Breast cancer and prostate cancer are the two most common invasive cancers in women and men, respectively. Although these cancers arise in organs that are different in terms of anatomy and physiological function both organs require gonadal steroids for their development, and tumours that arise from them are typically hormone-dependent and have remarkable underlying biological similarities. Many of the recent advances in understanding the pathophysiology of breast and prostate cancers have paved the way for new treatment strategies. In this Opinion article we discuss some key issues common to breast and prostate cancer and how new insights into these cancers could improve patient outcomes.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Huggins, C. Endocrine-induced regression of cancers. Cancer Res. 27, 1925–1930 (1967).
Beatson, G. T. Treatment of Cancer by Oöphorectomy. Br. Med. J. 2, 1195 (1926).
Ricke, W. A. et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 22, 1512–1520 (2008).
Price, D. et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J. Urol. 176, 965–970 (2006).
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S. & Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 93, 5925–5930 (1996).
McPherson, S. J. et al. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 148, 566–574 (2007).
Ellem, S. J. & Risbridger, G. P. Treating prostate cancer: a rationale for targeting local oestrogens. Nature Rev. Cancer 7, 621–627 (2007).
Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).
McPherson, S. J. et al. Estrogen receptor-b activated apoptosis in benign hyperplasia and cancer of the prostate is androgen-independent and TNF-α mediated. Proc. Natl Acad. Sci. USA 1 Feb 2010 (doi:10.1073/pnas.0905524107).
Birrell, S. N. et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 52, 459–467 (1995).
Birrell, S. N., Butler, L. M., Harris, J. M., Buchanan, G. & Tilley, W. D. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 21, 2285–2293 (2007).
Labrie, F. et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24, 152–182 (2003).
Shufelt, C. L. & Braunstein, G. D. Testosterone and the breast. Menopause Int. 14, 117–122 (2008).
Peters, A. A. et al. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res. 69, 6131–6140 (2009).
Ellem, S. J. & Risbridger, G. P. The dual, opposing roles of estrogen in the prostate. Ann. NY Acad. Sci. 1155, 174–186 (2009).
Dimitrakakis, C. et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10, 292–298 (2003).
Honma, N. et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 26, 3727–3734 (2008).
Murphy, C. E., Carder, P. J., Lansdown, M. R. & Speirs, V. Steroid hormone receptor expression in male breast cancer. Eur. J. Surg. Oncol. 32, 44–47 (2006).
Speirs, V. The evolving role of oestrogen receptor-b in clinical breast cancer. Breast Cancer Res. 10, 111 (2008).
Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M. & Tilley, W. D. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J. Clin. Oncol. 13, 1572–1577 (1995).
Kwiatkowska, E. et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin. Cancer Res. 9, 4452–4459 (2003).
Park, S. et al. Expression of androgen receptors in primary breast cancer. Ann. Oncol. 3 Nov 2009 (doi:10.1093/annonc/mdp510)
Edwards, D. P., Chamness, G. C. & McGuire, W. L. Estrogen and progesterone receptor proteins in breast cancer. Biochim. Biophys. Acta 560, 457–486 (1979).
Graham, J. D. & Clarke, C. L. Physiological action of progesterone in target tissues. Endocr. Rev. 18, 502–519 (1997).
Latil, A. et al. Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61, 1919–1926 (2001).
Purmonen, S., Manninen, T., Pennanen, P. & Ylikomi, T. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol. Rep. 19, 1627–1634 (2008).
Swarbrick, A., Lee, C. S., Sutherland, R. L. & Musgrove, E. A. Cooperation of p27Kip1 and p18INK4c in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell. Biol. 20, 2581–2591 (2000).
Graham, J. D. et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150, 3318–3326 (2009).
Lange, C. A. & Yee, D. Progesterone and breast cancer. Womens Health (Lond. Engl.) 4, 151–162 (2008).
Sikora, M. J. et al. The androgen metabolite 5α-androstane-3β, 17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res. Treat 115, 289–296 (2009).
de Jong, P. C. et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res. 57, 2109–2111 (1997).
Simpson, E. R. et al. Estrogen — the good, the bad, and the unexpected. Endocr. Rev. 26, 322–330 (2005).
Mohler, J. L. et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10, 440–448 (2004).
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653–4657 (2005).
Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407–6415 (2008).
Locke, J. A. et al. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J. Steroid Biochem. Mol. Biol. 115, 126–136 (2009).
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M. & Tilley, W. D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat Cancer 11, 459–476 (2004).
Santen, R. J., Brodie, H., Simpson, E. R., Siiteri, P. K. & Brodie, A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr. Rev. 30, 343–375 (2009).
Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563–4571 (2008).
Reid, A. H., Attard, G., Barrie, E. & de Bono, J. S. CYP17 inhibition as a hormonal strategy for prostate cancer. Nature Clin. Pract. Urol. 5, 610–620 (2008).
McKenna, N. J., Lanz, R. B. & O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20, 321–344 (1999).
Gao, X., Loggie, B. W. & Nawaz, Z. The roles of sex steroid receptor coregulators in cancer. Mol. Cancer 1, 7 (2002).
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W. & Greenberg, N. M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 120, 719–733 (2007).
O'Malley, B. W. & Kumar, R. Nuclear receptor coregulators in cancer biology. Cancer Res. 69, 8217–8222 (2009).
Iorns, E. et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91–104 (2008).
Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926–935 (2004).
Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965–968 (1997).
Fleming, F. J. et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J. Clin. Pathol. 57, 1069–1074 (2004).
Redmond, A. M. et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin. Cancer Res. 15, 2098–2106 (2009).
Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353–361 (2003).
Zhou, H. J. et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65, 7976–7983 (2005).
Yan, J. et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68, 5460–5468 (2008).
Ramamoorthy, S. & Nawaz, Z. E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl. Recept Signal 6, e006 (2008).
Dobson, R. Prostate cancer patients with BRCA2 mutation face poor survival. BMJ 337, a705 (2008).
Agalliu, I., Gern, R., Leanza, S. & Burk, R. D. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin. Cancer Res. 15, 1112–1120 (2009).
Wen, J., Li, R., Lu, Y. & Shupnik, M. A. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 28, 575–586 (2009).
Park, J. J. et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 60, 5946–5949 (2000).
Yeh, S. et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl Acad. Sci. USA 97, 11256–11261 (2000).
Shin, S. & Verma, I. M. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc. Natl Acad. Sci. USA 100, 7201–7206 (2003).
Buchanan, G. et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res. 67, 10087–10096 (2007).
Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
Maitland, N. J. & Collins, A. T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26, 2862–2870 (2008).
Davis, I. D. & Desai, J. Clinical use of therapies targeting tumor vasculature and stroma. Curr. Cancer Drug Targets. 8, 498–508 (2008).
Taylor, R. A. & Risbridger, G. P. Prostatic tumor stroma: a key player in cancer progression. Curr. Cancer Drug Targets. 8, 490–497 (2008).
Cunha, G. R. Mesenchymal-epithelial interactions: past, present, and future. Differentiation 76, 578–586 (2008).
Henshall, S. M. et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 61, 423–427 (2001).
Ayala, G. et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 9, 4792–4801 (2003).
Yanagisawa, N. et al. Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum. Pathol. 39, 282–291 (2008).
Risbridger, G. P. & Taylor, R. A. Minireview: regulation of prostatic stem cells by stromal niche in health and disease. Endocrinology 149, 4303–4306 (2008).
Hu, M. & Polyak, K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur. J. Cancer 44, 2760–2765 (2008).
Cunha, G. R. et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J. Steroid Biochem. Mol. Biol. 92, 221–236 (2004).
Schaeffer, E. M. et al. Androgen induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 27, 7180–7191 (2008).
Joesting, M. S. et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 65, 10423–10430 (2005).
Ma, X. J., Dahiya, S., Richardson, E., Erlander, M. & Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, 7 (2009).
Sadlonova, A. et al. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2, 9–21 (2009).
Trimboli, A. J. et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461, 1084–1091 (2009).
Zhu, P. et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124, 615–629 (2006).
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002).
DeNardo, D. G. & Coussens, L. M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9, 212 (2007).
Lehrer, S. et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 95, 961–962 (2005).
MacLennan, G. T. et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J. Urol. 176, 1012–1016 (2006).
Zheng, S. L. et al. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 66, 1556–1564 (2006).
Hagemann, T. et al. Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J. Immunol. 175, 1197–1205 (2005).
Zhu, X. et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10, R95 (2008).
Lin, W. W. & Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175–1183 (2007).
Gingras, S., Cote, S. & Simard, J. Multiple signal transduction pathways mediate interleukin-4-induced 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in normal and tumoral target tissues. J. Steroid Biochem. Mol. Biol. 76, 213–225 (2001).
Simard, J. & Gingras, S. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol. Cell Endocrinol. 171, 25–40 (2001).
Lou, W., Ni, Z., Dyer, K., Tweardy, D. J. & Gao, A. C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42, 239–242 (2000).
Giri, D. & Ittmann, M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 159, 139–147 (2001).
Liu, X. H. et al. Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem. Biophys. Res. Commun. 290, 249–255 (2002).
Lee, S. O., Chun, J. Y., Nadiminty, N., Lou, W. & Gao, A. C. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67, 764–773 (2007).
Sansone, P. et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117, 3988–4002 (2007).
Conticello, C. et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J. Immunol. 172, 5467–5477 (2004).
Lee, S. O. et al. Interleukin-4 activates androgen receptor through CBP/p300. Prostate 69, 126–132 (2009).
Jefford, M., Maraskovsky, E., Cebon, J. & Davis, I. D. The use of dendritic cells in cancer therapy. Lancet Oncol. 2, 343–353 (2001).
Higano, C. S. et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670–3679 (2009).
Ingle, J. N. Estrogen as therapy for breast cancer. Breast Cancer Res. 4, 133–136 (2002).
Li, C. I., Daling, J. R., Porter, P. L., Tang, M. T. & Malone, K. E. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 69, 6865–6870 (2009).
Huggins, C. & Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168, 9–12 (2002).
Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
Seidenfeld, J. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. 132, 566–577 (2000).
Stewart, H. J., Prescott, R. J. & Forrest, A. P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J. Natl Cancer Inst. 93, 456–462 (2001).
Bedognetti, D. et al. An open, randomised, multicentre, Phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur. Urol. 57, 238–245 (2010).
Smith, M. R. et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J. Urol. 179, 152–155 (2008).
Smith, M. R. et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J. Clin. Oncol. 26, 1824–1829 (2008).
Yamamoto, Y. et al. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer 15 Aug 2009 (doi:10.1007/s12282-009-0148-2).
Clarke, B. L. & Khosla, S. New selective estrogen and androgen receptor modulators. Curr. Opin. Rheumatol. 21, 374–379 (2009).
Ingle, J. N. et al. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res. Treat 98, 217–222 (2006).
Klotz, L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab. 22, 331–340 (2008).
Sartor, A. O. et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112, 2393–2400 (2008).
Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98, 1802–1810 (2003).
Gibson, L. J., Dawson, C. K., Lawrence, D. H. & Bliss, J. M. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev., CD003370 (2007).
Deeks, E. D. & Scott, L. J. Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs 69, 889–918 (2009).
Winer, E. P. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619–629 (2005).
Smith, M. R. et al. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 95, 1864–1868 (2002).
Sharma, R., Hamilton, A. & Beith, J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst. Rev., CD004562 (2008).
Klotz, L. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102, 1531–1538 (2008).
De Nunzio, C., Miano, R., Trucchi, A., Finazzi Agro, E. & Tubaro, A. Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin. Drug Metab. Toxicol. 4, 1561–1568 (2008).
Murtola, T. J. et al. Prostate cancer incidence among finasteride and α-blocker users in the Finnish Prostate Cancer Screening Trial. Br. J. Cancer 101, 843–848 (2009).
Kaplan, S. A. et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 73, 935–939 (2009).
Labrie, C., Cusan, L., Plante, M., Lapointe, S. & Labrie, F. Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer. J. Steroid Biochem. 28, 379–384 (1987).
Small, E. J. et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025–1033 (2004).
Ryan, C. J. et al. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J. Urol. 178, 2372–2377 (2007).
Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756–1764 (1996).
Ang, J. E., Olmos, D. & de Bono, J. S. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer 100, 671–675 (2009).
Antonarakis, E. S. & Eisenberger, M. A. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nature Clin. Pract. Oncol. 6, 12–13 (2009).
Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742–3748 (2009).
The authors thank C. Nelson, T. Hickey and L. Young for their insightful comments during the preparation of this article. This work was funded by the National Health and Medical Research Council of Australia (G.P.R. 545931, S.N.B. and W.D.T. 250373); the Susan G. Komen Foundation (W.D.T. ECTR111806); the National Breast Cancer Foundation (W.D.T. 399182); the US Army Medical Research and Materiel Command (G.P.R. PC073444, S.N.B., W.D.T. and DAMD 17-03-1-0618) and Prostate Cancer Foundation Australia (G.P.R. PG6). I.D.D. is supported in part by a Victorian Cancer Agency Clinical Researcher Fellowship and is an honorary NHMRC Practitioner Fellow.
The authors declare no competing financial interests.
About this article
Cite this article
Risbridger, G., Davis, I., Birrell, S. et al. Breast and prostate cancer: more similar than different. Nat Rev Cancer 10, 205–212 (2010). https://doi.org/10.1038/nrc2795
Scientific Reports (2021)
Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
Cancer & Metabolism (2020)
Performance-weighted-voting model: an ensemble machine learning method for cancer type classification using whole-exome sequencing mutation
Quantitative Biology (2020)
BMC Bioinformatics (2019)
Scientific Reports (2017)